Join our daily newsletter At The Bell to receive exclusive market insights
- Biotechnology company Cynata Therapeutics (CYP) will continue its MEND clinical trial after recommendation from the DSMB
- The Data Safety Monitoring Board (DSMB) aims to review and evaluate the available study data for participant safety, study conduct and progress
- The trial will investigate the safety and efficacy of Cynata’s mesenchymal stem cell (MSC) product in patients with respiratory failure
- Shares in Cynata are down a slight 0.8 per cent on the market and are trading at 62 cents
Biotechnology company Cynata Therapeutics (CYP) will continue its MEND clinical trial after recommendation from the DSMB.
The Data Safety Monitoring Board (DSMB) aims to review and evaluate the available study data for participant safety, study conduct and progress.
The board has recommended that the MEND clinical trial continue unchanged.
The MEND trial will investigate the safety and early efficacy of Cynata’s mesenchymal stem cell (MSC) product in patients with respiratory failure who meet the criteria for acute respiratory distress syndrome (ARDS).
Respiratory failure, including ARDS, is a severe and life-threatening illness, representing a major unmet medical need.
MSCs are adult stem cells found in a wide range of human tissue such as bone marrow, placenta and fat tissue.
They are multi-potent, which means they can produce more than one type of cell. For example, they can differentiate into cartilage cells, fat cells and bone cells.
They have been shown to ease regeneration and effects on the immune system without relying on engraftment (when transplanted cells start to grow and make healthy cells).
Chief Operating Officer Dr Killian Kelly commented on the recommendation.
“We thank the members of the independent DSMB for completing this important review,” Dr Kelly said.
“The DSMB’s positive recommendation is an important milestone, which enables us to continue patient enrolment in the MEND clinical trial and advance toward our goal of completing the trial later this year.”
Shares in Cynata were down a slight 0.8 per cent on the market and were trading at 62 cents at 10:59 am AEDT.
